We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05398029
Recruitment Status : Recruiting
First Posted : May 31, 2022
Last Update Posted : January 12, 2023
Sponsor:
Information provided by (Responsible Party):
Verve Therapeutics, Inc.

Brief Summary:
VT-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of VERVE-101 administered to patients with heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease (ASCVD), and uncontrolled hypercholesterolemia. VERVE-101 uses base-editing technology designed to disrupt the expression of the PCSK9 gene in the liver and lower circulating PCSK9 and LDL-C in patients with established ASCVD due to HeFH. This study is designed to determine the safety and pharmacodynamic profile of VERVE-101 in this patient population.

Condition or disease Intervention/treatment Phase
Heterozygous Familial Hypercholesterolemia Atherosclerotic Cardiovascular Disease Hypercholesterolemia Drug: VERVE-101 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Single ascending dose escalation followed by single dose expansion.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled Hypercholesterolemia
Actual Study Start Date : July 5, 2022
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: Part A: Single Ascending Dose Escalation
Participants will receive a single dose of VERVE-101 in multiple dose-escalation cohorts.
Drug: VERVE-101
Intravenous (IV) infusion.

Experimental: Part B: Single Dose Expansion
Participants will receive a single dose of VERVE-101 selected based on the doses studied in Part A.
Drug: VERVE-101
Intravenous (IV) infusion.




Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). [ Time Frame: up to Day 365 ]

Secondary Outcome Measures :
  1. Evaluation of maximum observed concentration (Cmax) [ Time Frame: up to Day 365 ]
  2. Evaluation of time to maximum observed concentration (tmax) [ Time Frame: up to Day 365 ]
  3. Evaluation of terminal elimination half-life (t1/2) [ Time Frame: up to Day 365 ]

Other Outcome Measures:
  1. Percent and absolute change from baseline in plasma PCSK9 concentration. [ Time Frame: up to Day 365 ]
  2. Percent and absolute change from baseline in LDL-C. [ Time Frame: up to Day 365 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and/or female participants 18 up to 75 years at time of signing of informed consent
  • Female participants not of child-bearing potential
  • Diagnosis of HeFH due to mutation in LDLR
  • Established ASCVD

Exclusion Criteria:

  • Diagnosis of HeFH due to mutation in PCSK9 or APOB, homozygous FH, compound heterozygous FH, double heterozygous FH
  • Active or history of chronic liver disease
  • Current treatment with PCSK9 monoclonal antibody therapy
  • Current or past treatment with inclisiran
  • Clinically significant or abnormal laboratory values as defined by the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05398029


Contacts
Layout table for location contacts
Contact: Clinical Operations at Verve Therapeutics 781-970-6833 verve101clinicaltrials@vervetx.com

Locations
Layout table for location information
New Zealand
Clinical Study Center Recruiting
Auckland, New Zealand
Clinical Study Center Recruiting
Christchurch, New Zealand
United Kingdom
Clinical Study Center Recruiting
London, United Kingdom
Sponsors and Collaborators
Verve Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Verve Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT05398029    
Other Study ID Numbers: VT-1001
First Posted: May 31, 2022    Key Record Dates
Last Update Posted: January 12, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Verve Therapeutics, Inc.:
VERVE-101
Familial Hypercholesterolemia
Cardiovascular Disease
Dose Escalation
Gene Editing
Base Editing
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Atherosclerosis
Hyperlipoproteinemia Type II
Hypercholesterolemia
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases